Olink Proteomics AB

Olink Proteomics AB is a company in Uppsala, Sweden that has taken part in 6 EU-funded projects since 2012, receiving €2.1M in EU funding.

EU funding received€2.1M
EU projects6
As coordinator0
Running now4
First EU project2012
Latest project2025
CountrySweden
EU registration (PIC)919441273
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Olink Proteomics AB's own share of each project, not the project's full budget.

  • Horizon Europe€1.3M · 4 projects
  • Horizon 2020€687k · 1 project
  • FP7 (2007 to 2013)€146k · 1 project

Projects

6 EU-funded projects, newest first. Each links to the official record.

  • OASISPartner

    OPTIMAL METHODS TO CHARACTERIZE ADC RESISTANCE IN SOLID TUMORS AND IDENTIFY CLINICALLY USEFUL BIOMARKERS

    Horizon Europe · 2025–2029 · Project on CORDIS ↗

    €391ktheir share
  • COMBATPartner

    Advancing Pandemic Preparedness: Innovative Multidisciplinary Strategies for COMBATing Severe Dengue

    Horizon Europe · 2024–2029 · Project on CORDIS ↗

    €450ktheir share
  • IMMERGEAssociated partner

    Storming Immune Monogenic Conditions through Multiomic and Gene Editing Approaches

    Horizon Europe · 2024–2027 · Project on CORDIS ↗

  • PREVALUNG EUPartner

    Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception.

    Horizon Europe · 2022–2027 · Project on CORDIS ↗

    €427ktheir share
  • ULTRADIANPartner

    Dynamic hormone diagnostics

    Horizon 2020 · 2015–2020 · Project on CORDIS ↗

    €687ktheir share
  • IBD-CHARACTERPartner

    Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study

    FP7 (2007 to 2013) · 2012–2017 · Project on CORDIS ↗

    €146ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • DNA
  • RNA
  • RNA viruses
  • cell signaling
  • endocrinology
  • epilepsy
  • gene therapy
  • health economics
  • homeostasis
  • immunology
  • inflammatory bowel disease
  • machine learning
  • mass spectrometry
  • mortality

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime